Voyager Therapeutics Conference Call Summary Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Focus**: Development of gene therapies targeting neurodegenerative diseases, particularly Alzheimer's disease Key Industry Insights - **Year of Tau**: 2026 is referred to as the "year of tau" for Voyager, emphasizing the company's focus on tau-related therapies [2] - **Tau vs. A-beta**: The discussion highlights the ongoing debate regarding the role of tau and amyloid-beta (A-beta) in Alzheimer's disease, with evidence suggesting tau may be a more significant driver of cognitive decline [4][5][6] Core Developments 1. **Tau-targeted Assets**: - Two main assets targeting tau: an antibody and a gene therapy for tau knockdown [2] - Anticipated tau PET imaging data by the end of 2026 [2] - Gene therapy aims for a robust knockdown of tau in the brain, with expected reductions in the 50%-75% range across various cortical regions [12] 2. **Capsid Technology**: - Introduction of newly discovered blood-brain barrier (BBB)-penetrant capsids into clinical trials [2] - Two programs utilizing these capsids: one for tau knockdown and another partnered with Neurocrine for Friedreich's ataxia [3] - The goal is to demonstrate proof of concept for gene expression in the brain [3] 3. **Regulatory Engagement**: - Positive interactions with the FDA regarding the development of the tau knockdown gene therapy program [15][17] - Plans to use tau PET imaging to assess the reduction of pathological tau as a primary endpoint [17] Clinical Development and Strategy - **BIIB080 Data**: The upcoming data from BIIB080 is expected to be a significant catalyst for the gene therapy program, providing insights into the necessary tau reduction for clinical benefits [8][10] - **Antibody Development**: Voyager's antibody approach focuses on specific pathological forms of tau, with hopes of demonstrating efficacy in tau PET imaging and clinical outcomes [20][22][29] Market Considerations - **Timing of Intervention**: The company believes that interventions targeting tau may not need to occur as early as those targeting amyloid, suggesting a potential window for treatment even in mild to moderate dementia stages [30][34] - **Partnership Strategy**: Voyager is actively seeking partnerships to expand its reach and capabilities, leveraging collaborations with companies like Neurocrine, Novartis, and AstraZeneca [44][46] Additional Insights - **Novel Shuttle Technology**: Voyager is exploring the use of ALPL as a receptor for BBB penetration, which may offer advantages over traditional methods [37][39] - **Safety Considerations**: The potential safety risks associated with ALPL are acknowledged, particularly concerning severe loss of function leading to hypophosphatasia [43] Conclusion Voyager Therapeutics is positioned to make significant advancements in the treatment of neurodegenerative diseases, particularly through its focus on tau-targeted therapies and innovative delivery mechanisms. The upcoming data releases and regulatory interactions will be critical in shaping the company's future trajectory in the biotech landscape.